Global investment firm Carlyle announced today that it has agreed to acquire Abingworth, a transatlantic life sciences investment firm with over $2bn in assets under management (AUM), to bolster Carlyle’s leading global healthcare franchise.
Abingworth has successfully deployed $3 billion of equity behind 179 life sciences companies through 14 dedicated life sciences funds. During this time, 73 portfolio companies have transitioned onto the public markets through initial public offerings (IPOs) and 46 companies have undergone a merger or acquisition. Importantly, 26 new medicines, developed by companies funded by and built by Abingworth, have been approved by the US Food & Drug Administration in the past nine years.
Today’s announcement demonstrates an extension of Carlyle’s long-term global commitment to leadership in healthcare in which it has invested over $22 billion across buyout and growth equity since inception, including in transformative pharma and life sciences businesses such as PPD, Adicon, Curia, Piramal, Saama, SeQuent, TriNetX, and Unchained Labs.
Read more: Press Release
